Welcome to our dedicated page for Cell Source news (Ticker: CLCS), a resource for investors and traders seeking the latest updates and insights on Cell Source stock.
Cell Source, Inc. (CLCS) is a biotechnology innovator developing Veto Cell immunotherapy platforms to address critical challenges in stem cell transplantation and immune tolerance. This page serves as the definitive source for verified company announcements, research developments, and regulatory milestones.
Investors and medical professionals will find timely updates on clinical trial progress, strategic partnerships with leading research institutions, and financial disclosures. Our curated news feed includes press releases covering therapeutic advancements for hematologic cancers, genetic disorders, and organ transplant innovations.
Key updates focus on CLCS's proprietary technology applications, including off-the-shelf CAR-T therapies and mismatched donor transplant solutions. All content is sourced directly from company filings and official communications to ensure accuracy.
Bookmark this page for streamlined access to CLCS's latest developments in cellular therapy. Check regularly for updates on FDA submissions, peer-reviewed study publications, and licensing agreements that shape the future of transplantation medicine.
Cell Source (OTCQB:CLCS) presented groundbreaking preclinical findings at the 2024 American Society of Hematology Annual Meeting, demonstrating how their proprietary Veto Cell technology can overcome NK cell-mediated rejection in allogeneic cell therapy. The research shows Veto Tcm cells can suppress NK cell activity without triggering host T-cell proliferation or graft-versus-host disease by down-regulating the DNAM-1 activating receptor on NK cells.
This breakthrough could enable the development of off-the-shelf CAR-T therapies that are safer, more cost-effective, and scalable compared to existing treatments. The technology's ability to suppress NK-mediated rejection represents a significant advancement in addressing current cellular therapy limitations, particularly in facilitating safer mismatched donor stem cell and organ transplantation.
Cell Source (OTCQB:CLCS) has announced promising interim results from its Phase 1/2 First-in-Human clinical trial of Veto Cell technology at MD Anderson Cancer Center. The trial, involving 15 patients with hematologic diseases, demonstrated successful engraftment without severe graft-versus-host disease (GvHD) using T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning. Key findings include consistent engraftment at 42 days post-transplant, no Veto Cell-related toxicity, and an enhanced protocol using mild conditioning with Rituximab. The technology aims to make transformative treatments more accessible for conditions ranging from leukemia to sickle cell disease.
Cell Source, Inc. (OTC: CLCS) announced the appointment of Darlene Soave to its Board of Directors, effective May 25, 2021. Soave brings over 40 years of entrepreneurial leadership experience, previously co-founding Soave Enterprises, which generates over $1.8 billion in annual revenues. This leadership change comes at a pivotal time as Cell Source advances its first Phase I/II clinical trial, aimed at proving the safety and efficacy of its innovative Veto Cell technology, designed for improved stem cell and organ transplants.
Cell Source, Inc. (OTC: CLCS) announced the issuance of two USPTO patents for its innovative Veto Cell technology, enhancing mismatched donor stem cell transplants and treating blood diseases. The first patent focuses on Veto Cells generated from memory T cells, facilitating patient acceptance and fighting infections. The second patent describes Veto Cells as companion cells for CAR-T and NK cell therapies, preventing graft rejection. These advancements position Veto Cells as a versatile immunotherapy platform, with applications in cancer treatment and beyond, bolstering the company's growth potential.
Cell Source (OTC: CLCS) has made significant advancements in Veto Cell based immunotherapy, achieving a key breakthrough in treating sickle cell disease (SCD). Their newly developed mouse model protocol demonstrates durable prevention of SCD pathology, with complete conversion to normal, donor-derived red blood cells. Published in the BMT Journal, this study addresses major challenges in mismatched donor stem cell transplants. The ongoing Phase 1/2 clinical trial is testing Veto Cells for safety and efficacy in hematological diseases, offering hope for safe and effective treatments.
Cell Source, Inc. (OTC: CLCS) announced that Dr. Joseph Rosenthal has joined its Scientific Advisory Board. Dr. Rosenthal is a renowned expert in pediatric hematology-oncology at City of Hope and brings extensive experience in childhood cancer treatments and stem cell transplantation. His addition comes as Cell Source's Veto Cell technology transitions into the first human clinical trials, a significant milestone for the company. Chairman Dennis Brown expressed optimism about Dr. Rosenthal's contributions to advancing their innovative immunotherapy technologies.
